UK's No-Deal Brexit Plans Revealed For Pharma Sector
Executive Summary
The UK government has published “technical notices” explaining what would change in the drug regulatory arena in the event of a no-deal Brexit, and what stakeholders need to do to prepare. Companies will be expected to stockpile medicines in the immediate run-up to the UK's departure from the EU.
You may also be interested in...
EU Offers Flexibility On UK Batch Release In No-Deal Brexit Scenario
The UK has been offered an exemption from the requirement for UK medicines to undergo EU batch testing and release before they can be marketed in member states of the EU, but only in specific circumstances.
MHRA Tackles Post Brexit Distribution Worries
Companies importing medicines from the EU into the UK in the event of a no-deal Brexit could face a lot of complications. The UK medicines regulator, the MHRA, has come up with one idea for easing the import requirements in such a scenario.
Brexit: EU Countries Dragging Feet On At-Risk Medicines
The EU regulatory network is finding it difficult to identify non-centrally authorized medicines that are at risk of Brexit-related shortages, a workshop on medicines availability has heard.